Identification of Potential Prognostic Competing Triplets in High-Grade Serous Ovarian Cancer

Zhao, Jian; Song, Xiaofeng; Xu, Tianyi; Yang, Qichang; Liu, Jingjing; Jiang, Bin; Wu, Jing

doi:10.3389/fgene.2020.607722

Cited by 23 publications

(19 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer is famous for its high fatality rate (14). Exploring the molecular mechanism of OC is conducive to finding effective therapeutic targets (15,16). Increasing evidence has suggested that CDK4/6 play important roles in the progression and prognosis of multiple cancers, including OC (17).…”

Section: Discussionmentioning

confidence: 99%

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

BackgroundOvarian cancer (OC) is one of the most lethal gynecologic cancers. Growing evidence has proven that CDK4/6 plays a key role in tumor immunity and the prognosis of many cancers. However, the expression and function of CDK4/6 in OC remain unclear. Therefore, we aimed to explore the influence of CDK4/6 in OC, especially on immunity.MethodsWe analyzed CDK4/6 expression and prognosis using The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Genotype Tissue Expression (GTEx) data. Subsequently, we used the cytoHubba plug-in of Cytoscape software and starBase to identify the noncoding RNAs (ncRNAs) regulating CDK4/6. Finally, we verified the effect of CDK4/6 on immunity in OC cell lines and animal models.ResultsCDK4/6 expression was higher in OC tissues than in normal ovarian tissues, and the high expression levels of CDK4/6 contributed to the immunosuppressive state of OC and were thus related to the poor prognosis of OC patients. This was also in general agreement with the results of OC cell line and animal experiments. Mechanistically, the CDK4/6 inhibitor palbociclib increased the secretion of interferon (IFN)-γ and the interferon-stimulated gene (ISG) response, thereby upregulating the expression of antigen-presenting molecules; this effect was partly dependent on the STING pathway and thus activated immunity in OC. Additionally, according to public data, the LRRC75A-AS1-hsa-miR-330-5p axis could inhibit the immune response of OC patients by upregulating CDK4/6, leading to a poor prognosis.ConclusionCDK4/6 affects the immune microenvironment of OC and correlates with the prognosis of OC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“… 31 In the miRNA–lncRNA pair centered regulatory network consisting of competing triplets in ovarian cancer, AC099850.4 is one of the top five lncRNAs with the most connections. 32 Studies have shown that LINC02154 is significantly upregulated in renal cell carcinoma, and its high expression is one of the risk factors for poor prognosis. It is involved in the construction of a model for predicting the prognosis of patients with renal cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

A Novel Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Patients with Papillary Renal Cell Carcinoma

Dang

Jin

Nan

et al. 2022

IJGM

View full text Add to dashboard Cite

Papillary renal cell carcinoma (PRCC) is a common renal cell carcinoma. Recent studies have reported that ferroptosis is involved in the occurrence and development of tumors. Long non-coding RNAs can be used as independent biomarkers for the diagnosis and prognosis of a variety of tumors. Methods: Gene expression profile and clinical information of patients with PRCC were obtained from The Cancer Genome Atlas (TCGA) database. Lasso penalized Cox regression and univariate Cox regression analysis were utilized for model construction. The Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves were plotted to validate the predictive effect of the prognostic signature. Immune cell infiltration and immune function were compared between the high-risk and low-risk groups. Chemotherapy sensitivity analysis was also performed. Results: We constructed a prognostic signature consisting of 15 ferroptosis-related lncRNAs. The K-M curves validated the fine predictive accuracy of the prognostic signature (p < 0.001). The area under the curve (AUC) of the lncRNA signature was 0.930, exhibiting robust prognostic capacity. The high-risk group had a greater degree of immune cell infiltration than the low-risk group. Significant differences in inflammation promotion, parainflammation, and type I IFN response were noted between the low-risk and high-risk groups (p < 0.01). The expression levels of immune checkpoints including CD80, IDO1, and LAG3 were significantly higher in the high-risk group than in the low-risk group (p < 0.05). Chemotherapy sensitivity analysis showed that MNX1-AS1, ZFAS1, MIR4435-2HG, and ADAMTS9-AS1 were significantly correlated with the sensitivity of some chemotherapy drugs (p < 0.05). Conclusion:We demonstrated that a ferroptosis-related lncRNA prognostic signature could be a novel biomarker for PRCC.

show abstract

“…Besides, overexpression of MIR210HG promotes the progression of colorectal adenocarcinoma via modulating hypoxia (He et al, 2019) and was associated with worse overall survival in colon cancer patients (Ruan et al, 2019). AC099850.4 is one of the top lncRNA in miRNA-lncRNA network and may be associated with tumor division, tumor proliferation, cell cycle and so on in ovarian cancer (Zhao et al, 2020). Higher expression of NRAV was associated with advanced clinical stage, poor prognosis and immunologic characteristics in hepatocellular carcinoma patients (Feng et al, 2021;Xu et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma

Zhou

Zhang

2021

Front. Genet.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most general malignant tumors. Hypoxia is a critical clinical characteristic and acts as a significant part in the development and cancers’ prognosis. The prognostic value and biological functions of hypoxia-related lncRNAs in hepatocellular carcinoma is little known. Thus, we aim to establish a hypoxia-related lncRNA signature to predict the HCC patients’ survival. First, we extracted the hypoxia-related genes and expression of lncRNAs from the MSigDB and TCGA database, respectively. The co-expression analysis among hypoxia-related mRNAs and lncRNAs was employed to identify hypoxia-related lncRNAs. Then, comprehensive analyses of lncRNAs expression level and survival data were applied to establish the signature. We built a prognostic signature on the foundation of the three differently expressed hypoxia-related lncRNAs. Kaplan-Meier curves indicated the low-risk group is associated with better survival. The 1−, 3−, and 5 years AUC values of the signature were 0.805, 0.672 and 0.63 respectively. The test set performed consistent outcomes. A nomogram was built grounded on the risk score and clinicopathological features. GSEA showed the immune-related pathways in high-risk group, while metabolism-related pathways in low-risk group. Besides, we found this model was correlated with the clinical features, tumor immune cell infiltration, immune checkpoints, and m6A-related genes. Finally, a novel signature based on hypoxia-related lncRNAs was established and validated for predicting HCC patients’ survival and may offer some useful information for immunotherapies.

show abstract

Identification of Potential Prognostic Competing Triplets in High-Grade Serous Ovarian Cancer

Cited by 23 publications

References 54 publications

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer

A Novel Ferroptosis-Related lncRNA Signature for Prognosis Prediction in Patients with Papillary Renal Cell Carcinoma

Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma

Contact Info

Product

Resources

About